

Entheon Biomedical Further Strengthens Advisory Board with Appointment of Dr. Andy Greenshaw

Vancouver, British Columbia--(Newsfile Corp. - July 28, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ("**Entheon**" or the "**Company**"), a biotechnology company focused on developing psychedelic medicines to treat addiction, is pleased to announce the addition of Dr. Andrew (Andy) Greenshaw, Professor of Psychiatry and Neuroscience and Associate Chair (Research) for Psychiatry at the University of Alberta.

Dr. Greenshaw is a Fellow of the Royal Society of Arts; a Fellow of the Canadian College of Neuropsychopharmacology (CCNP), for which he served as President from 2000-2002; and a fellow of the Collegium Internationale Neuropsychopharmacologicum (CINP). Andy served as University of Alberta Associate Vice President (Research) and was a member of the Scientific Advisory Board of the CIHR Institute of Neuroscience Mental Health & Addiction from 2012-2016. Active research includes applications of machine learning and data mining as a member of the University of Alberta computational psychiatry group. Dr. Greenshaw has significant experience involving the research in psychiatry and mental health with a broad range of scientific interests that include computational and biological psychiatry and behavioral neuroscience.

With his research and insight, Dr. Greenshaw has held many roles within the greater community. He is the Scientific Director of the APEC Digital Hub for Mental Health, a Director on the Board of Mental Health Research Canada and continues to provide leadership for Canadian Institutes of Health Research grant review panels.

"As we advance our knowledge of mental health through continued research, I look forward to working with Entheon as they continue to clinically develop DMT. Understanding the biological and physiological impacts of psychedelic therapeutics will be a critical component to unlocking the promising potential of psychedelic drug augmentation of therapeutic responses in addiction and mental health," said Dr. Greenshaw.

"We would like to extend a warm welcome to Andy as he joins the team at Entheon. His knowledge and insight will be paramount as we continue to navigate the development of DMT as a treatment for addiction disorders," said Chief Executive Officer, Timothy Ko. "Furthermore, Dr. Greenshaw's addition brings deep bench strength in the realm of substance use risk, and further strengthens our Advisory Board."

About Entheon Biomedical Corp.

Entheon is a biotechnology research and development company committed to developing and commercializing a portfolio of safe and effective N,N-dimethyltryptamine based psychedelic therapeutic products ("**DMT Products**") for the purposes of treating addiction and substance use disorders. Subject to obtaining all requisite regulatory approvals and permits, Entheon intends to generate revenue through the sale of its DMT Products to physicians, clinics and licensed psychiatrists in the United States, certain countries in the European Union and throughout Canada. In addition, Entheon's subsidiary, HaluGen Life Sciences, has launched the Psychedelic Genetics Test Kit which is now available in the Canada and the United States and can be purchased at www.HaluGen.com.

About Dr. Andrew (Andy) Greenshaw

Dr. Greenshaw is a Professor of Psychiatry and Neuroscience at the University of Alberta. He is a Fellow of the Canadian College of Neuropsychopharmacology (CCNP), for which he served as President from 2000-02, and a Fellow of the Collegium Internationale Neuropsychopharmacologicum (CINP). He has

served on various national and international boards including Canadian Psychiatric Research Foundation, Institute of Health Economics, Saskatchewan Health Research Foundation and University of the Arctic and the Alberta Addictions and Mental Health Research Partnership Committee.

On Behalf of the Board of Directors,

"Timothy Ko"

Timothy Ko, CEO

For more information, please contact the Company at:

Enttheon Biomedical Corp.

Joseph Cullen, Investor Relations

Telephone: +1 (778) 919-8615

Joe@enttheonbiomedical.com

<https://enttheonbiomedical.com/>

For media inquiries, please contact Crystal Quast at:

Bullseye Corporate

Crystal Quast

Telephone: +1 (647) 529-6364

Quast@BullseyeCorporate.com

Cautionary Note on Forward-Looking Information

This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward-looking statements or information. More particularly and without limitation, this news release contains forward-looking statements and information relating to the engagement and advisory services of Dr. Andrew Greenshaw as "Advisor", the development of the Company's clinical program, and other matters. The forward-looking statements and information are based on certain key expectations and assumptions made by management of the Company. Although management of the Company believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information since no assurance can be given that they will prove to be correct.

Forward-looking statements and information are provided for the purpose of providing information about the current expectations and plans of management of the Company relating to the future. Readers are cautioned that reliance on such statements and information may not be appropriate for other purposes, such as making investment decisions. Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. These include, but are not limited to, the Company's ability to raise further capital and the Company's ability to obtain regulatory and exchange approvals. Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this news release. Readers are cautioned that the foregoing list of factors is not exhaustive. The forward-looking statements and information contained in this news release are made as of the date hereof and no undertaking is given to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws. The forward-looking statements or information contained in this news release are expressly qualified by this cautionary statement.

Neither the CSE nor the Investment Industry Regulatory Organization of Canada accepts responsibility for the adequacy or accuracy of this release.

To view the source version of this press release, please visit
<https://www.newsfilecorp.com/release/91385>